Carnino F, Fuda G, Ciccone G, Iskra L, Guercio E, Dadone D, Conte P F
S. Anna Hospital, Turin, Italy.
Gynecol Oncol. 1997 Jun;65(3):467-72. doi: 10.1006/gyno.1997.4633.
From 1979 to 1984, 127 patients operated on for ovarian cancer underwent pelvic, para-aortic, or pelvic and para-aortic lymph node sampling. Forty-seven patients proved to be stage I(14 IA and 33 IC), 14 were stage II(3 IIA, 8 IIB, and 3 IIC), 58 were stage III (7 IIIA, 13 IIIB, and 38 IIIC), and 8 were stage IV. Positive lymph nodes were found in 4.2% of patients at stage I, 35.7% at stage II, 41.3% at stage III, and 87.5% at stage IV. With regard to grading, positive lymph nodes were found in 4.4% of G1, in 21.6% of G2, and in 49.1% of G3. A significant increase in survival (P = 0.04) was found for patients classified as stage IIIC only according to lymph node involvement compared to patients in peritoneal stage IIIC with positive lymph nodes (3-year survival: 46% vs 12%). A small increase in survival was observed for N- patients compared to N+ patients, at both stage III and IV, even with same residual tumor size, but the difference is not statistically significant. All other things being equal, because the prevalence of lymph node positivity depends closely on the number of lymph nodes removed and examined (OR = 3.9 for >10 lymph nodes removed compared to 1-5 lymph nodes removed), lymph node sampling does not seem to be a reliable method for evaluating the retroperitoneal status. With regard to the therapeutic role of systematic lymphadenectomy, few data in literature are available and, most important, are not derived from experimental studies. Probably, only randomized studies with a large number of patients will provide useful answers.
1979年至1984年期间,127例接受卵巢癌手术的患者接受了盆腔、腹主动脉旁或盆腔及腹主动脉旁淋巴结取样。47例患者被证实为Ⅰ期(14例ⅠA期和33例ⅠC期),14例为Ⅱ期(3例ⅡA期、8例ⅡB期和3例ⅡC期),58例为Ⅲ期(7例ⅢA期、13例ⅢB期和38例ⅢC期),8例为Ⅳ期。Ⅰ期患者中4.2%发现淋巴结阳性,Ⅱ期为35.7%,Ⅲ期为41.3%,Ⅳ期为87.5%。在分级方面,G1级患者中4.4%发现淋巴结阳性,G2级为21.6%,G3级为49.1%。仅根据淋巴结受累情况分类为ⅢC期的患者与腹膜ⅢC期且淋巴结阳性的患者相比,生存率有显著提高(P = 0.04)(3年生存率:46%对12%)。在Ⅲ期和Ⅳ期,即使残留肿瘤大小相同,N-患者与N+患者相比生存率略有提高,但差异无统计学意义。在其他条件相同的情况下,由于淋巴结阳性的发生率密切取决于切除和检查的淋巴结数量(与切除1 - 5个淋巴结相比,切除>10个淋巴结时的比值比为3.9),淋巴结取样似乎不是评估腹膜后状态的可靠方法。关于系统性淋巴结清扫术的治疗作用,文献中的数据很少,而且最重要的是,并非来自实验研究。可能只有大量患者参与的随机研究才能提供有用的答案。